Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

1.

Curcumin targets the AKT-mTOR pathway for uterine leiomyosarcoma tumor growth suppression.

Wong TF, Takeda T, Li B, Tsuiji K, Kondo A, Tadakawa M, Nagase S, Yaegashi N.

Int J Clin Oncol. 2014 Apr;19(2):354-63. doi: 10.1007/s10147-013-0563-4. Epub 2013 May 11.

PMID:
23666561
[PubMed - in process]
2.

Epigallocatechin-3-gallate potentiates curcumin's ability to suppress uterine leiomyosarcoma cell growth and induce apoptosis.

Kondo A, Takeda T, Li B, Tsuiji K, Kitamura M, Wong TF, Yaegashi N.

Int J Clin Oncol. 2013 Jun;18(3):380-8. doi: 10.1007/s10147-012-0387-7. Epub 2012 Feb 15.

PMID:
22350026
[PubMed - indexed for MEDLINE]
3.

Curcumin induces cross-regulation between autophagy and apoptosis in uterine leiomyosarcoma cells.

Li B, Takeda T, Tsuiji K, Wong TF, Tadakawa M, Kondo A, Nagase S, Yaegashi N.

Int J Gynecol Cancer. 2013 Jun;23(5):803-8. doi: 10.1097/IGC.0b013e31828c9581.

PMID:
23532091
[PubMed - indexed for MEDLINE]
4.

Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition.

Wong TF, Takeda T, Li B, Tsuiji K, Kitamura M, Kondo A, Yaegashi N.

Gynecol Oncol. 2011 Jul;122(1):141-8. doi: 10.1016/j.ygyno.2011.03.001. Epub 2011 Mar 29.

PMID:
21450334
[PubMed - indexed for MEDLINE]
5.

The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.

Setsu N, Yamamoto H, Kohashi K, Endo M, Matsuda S, Yokoyama R, Nishiyama K, Iwamoto Y, Dobashi Y, Oda Y.

Cancer. 2012 Mar 15;118(6):1637-48. doi: 10.1002/cncr.26448. Epub 2011 Aug 11.

PMID:
21837670
[PubMed - indexed for MEDLINE]
Free Article
6.

Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-κB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IκB kinase complex signaling axis in adenoid cystic carcinoma.

Sun ZJ, Chen G, Zhang W, Hu X, Liu Y, Zhou Q, Zhu LX, Zhao YF.

Mol Pharmacol. 2011 Jan;79(1):106-18. doi: 10.1124/mol.110.066910. Epub 2010 Oct 19. Erratum in: Mol Pharmacol. 2011 Mar;79(3):628-30.

PMID:
20959361
[PubMed - indexed for MEDLINE]
Free Article
7.

Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.

Yamada Y, Kohashi K, Fushimi F, Takahashi Y, Setsu N, Endo M, Yamamoto H, Tokunaga S, Iwamoto Y, Oda Y.

Cancer. 2014 Mar 15;120(6):864-76. doi: 10.1002/cncr.28506. Epub 2013 Dec 18.

PMID:
24353015
[PubMed - indexed for MEDLINE]
8.

Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.

Dhingra S, Rodriguez ME, Shen Q, Duan X, Stanton ML, Chen L, Zhang R, Brown RE.

Int J Clin Exp Pathol. 2010 Jan 28;4(2):134-46.

PMID:
21326806
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The phosphatidylinositol 3' kinase-Akt-mammalian target of rapamycin pathway in smooth muscle tumors of the uterus: selected protein expression patterns and their clinicopathologic implications.

Fadare O, Renshaw I, Olson SJ, Liang SX.

Int J Gynecol Pathol. 2011 May;30(3):244-51. doi: 10.1097/PGP.0b013e3181fde2ac.

PMID:
21464729
[PubMed - indexed for MEDLINE]
10.

Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.

Brewer Savannah KJ, Demicco EG, Lusby K, Ghadimi MP, Belousov R, Young E, Zhang Y, Huang KL, Lazar AJ, Hunt KK, Pollock RE, Creighton CJ, Anderson ML, Lev D.

Clin Cancer Res. 2012 Sep 1;18(17):4633-45. doi: 10.1158/1078-0432.CCR-12-0436. Epub 2012 Jul 20.

PMID:
22821997
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling.

Johnson SM, Gulhati P, Arrieta I, Wang X, Uchida T, Gao T, Evers BM.

Anticancer Res. 2009 Aug;29(8):3185-90. Erratum in: Anticancer Res. 2009 Oct;29(10):4315.

PMID:
19661333
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.

Du W, Gerald D, Perruzzi CA, Rodriguez-Waitkus P, Enayati L, Krishnan B, Edmonds J, Hochman ML, Lev DC, Phung TL.

Lab Invest. 2013 Oct;93(10):1115-27. doi: 10.1038/labinvest.2013.98. Epub 2013 Aug 12.

PMID:
23938603
[PubMed - indexed for MEDLINE]
13.

Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism.

Yu S, Shen G, Khor TO, Kim JH, Kong AN.

Mol Cancer Ther. 2008 Sep;7(9):2609-20. doi: 10.1158/1535-7163.MCT-07-2400.

PMID:
18790744
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways.

Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y.

Mol Pharmacol. 2007 Jul;72(1):29-39. Epub 2007 Mar 29.

PMID:
17395690
[PubMed - indexed for MEDLINE]
Free Article
15.

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.

Clin Cancer Res. 2004 Dec 1;10(23):8059-67.

PMID:
15585641
[PubMed - indexed for MEDLINE]
Free Article
16.

Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.

Wang D, Veena MS, Stevenson K, Tang C, Ho B, Suh JD, Duarte VM, Faull KF, Mehta K, Srivatsan ES, Wang MB.

Clin Cancer Res. 2008 Oct 1;14(19):6228-36. doi: 10.1158/1078-0432.CCR-07-5177.

PMID:
18829502
[PubMed - indexed for MEDLINE]
Free Article
17.
18.

Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.

Lin CY, Hsu SC, Lee HS, Lin SH, Tsai CS, Huang SM, Shih CC, Hsu YJ.

J Vasc Surg. 2013 Feb;57(2):475-85. doi: 10.1016/j.jvs.2012.07.037. Epub 2012 Dec 21.

PMID:
23265586
[PubMed - indexed for MEDLINE]
19.

Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway.

Italiano A, Kind M, Stoeckle E, Jones N, Coindre JM, Bui B.

Anticancer Drugs. 2011 Jun;22(5):463-7. doi: 10.1097/CAD.0b013e3283442074.

PMID:
21301319
[PubMed - indexed for MEDLINE]
20.

Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.

Mallon R, Hollander I, Feldberg L, Lucas J, Soloveva V, Venkatesan A, Dehnhardt C, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Gibbons J.

Mol Cancer Ther. 2010 Apr;9(4):976-84. doi: 10.1158/1535-7163.MCT-09-0954. Epub 2010 Apr 6.

PMID:
20371716
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk